TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-12.46%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.63B
AUM Growth
+$2.63B
(-2.1%)
Cap. Flow
+$309M
Cap. Flow
% of AUM
11.73%
Top 10 Holdings %
Top 10 Hldgs %
44.7%
Holding
148
New
38
Increased
32
Reduced
10
Closed
13
Top Buys
| 1 |
UnitedHealth
UNH
|
$36.3M |
| 2 |
Biogen
BIIB
|
$33.3M |
| 3 |
Merck
MRK
|
$24.5M |
| 4 |
United Therapeutics
UTHR
|
$24M |
| 5 |
MDCO
Medicines Co
MDCO
|
$23.7M |
Top Sells
| 1 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
$26.5M |
| 2 |
Amgen
AMGN
|
$24.3M |
| 3 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$23.7M |
| 4 |
CELG
Celgene Corp
CELG
|
$23.3M |
| 5 |
ACOR
Acorda Therapeutics, Inc.
ACOR
|
$22.7M |
Sector Composition
| 1 | Healthcare | 85.75% |
| 2 | Real Estate | 3.66% |
| 3 | Financials | 1.38% |
| 4 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $218M | 7.84% | 2,221,431 +141,700 | +7% | +$13.9M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $185M | 6.66% | 1,713,634 -215,600 | -11% | -$23.3M |
|
|
3
Biogen
BIIB
$19.4B
| $136M | 4.9% | 467,183 +113,950 | +32% | +$33.3M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $105M | 3.78% | 1,009,903 +112,000 | +12% | +$11.7M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $99.6M | 3.58% | 636,805 +52,500 | +9% | +$8.21M |
|
6
Incyte
INCY
$16.5B
| $97.1M | 3.49% | 880,461 | – | – |
|
7
Johnson & Johnson
JNJ
$427B
| $87.8M | 3.16% | 940,988 +56,376 | +6% | +$5.26M |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $86.4M | 3.1% | 317,686 -26,000 | -8% | -$7.07M |
|
9
Viatris
VTRS
$12.3B
| $82M | 2.95% | 2,035,657 +198,652 | +11% | +$8M |
|
10
Teva Pharmaceuticals
TEVA
$21.1B
| $78.2M | 2.81% | 1,385,594 -2,000 | -0.1% | -$113K |
|
11
Regeneron Pharmaceuticals
REGN
$61.5B
| $71.8M | 2.58% | 154,266 -32,900 | -18% | -$15.3M |
|
12
Alkermes
ALKS
$4.78B
| $68.4M | 2.46% | 1,165,818 +130,348 | +13% | +$7.65M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $60.1M | 2.16% | 570,477 +35,500 | +7% | +$3.74M |
|
14
Pfizer
PFE
$141B
| $56.6M | 2.03% | 1,802,291 +164,050 | +10% | +$5.15M |
|
15
Illumina
ILMN
$15.8B
| $53M | 1.9% | 301,341 +71,700 | +31% | +$12.6M |
|
|
16
Amgen
AMGN
$155B
| $44.5M | 1.6% | 321,640 -175,640 | -35% | -$24.3M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $36.3M | 1.31% | 331,931 | – | – |
|
|
18
UnitedHealth
UNH
$281B
| $36.3M | 1.3% | +312,600 | New | +$36.3M |
|
|
19
Merck
MRK
$210B
| $33.6M | 1.21% | 681,097 +496,097 | +268% | +$24.5M |
|
20
Bristol-Myers Squibb
BMY
$96B
| $31.7M | 1.14% | 535,240 | – | – |
|
|
AKRX
21
DELISTED
Akorn, Inc.
AKRX
| $24.2M | 0.87% | 849,482 | – | – |
|
|
22
United Therapeutics
UTHR
$13.8B
| $24M | 0.86% | +182,600 | New | +$24M |
|
23
Molina Healthcare
MOH
$9.8B
| $24M | 0.86% | 347,901 | – | – |
|
|
MDCO
24
DELISTED
Medicines Co
MDCO
| $23.7M | 0.85% | +624,300 | New | +$23.7M |
|
25
Humana
HUM
$36.5B
| $23.1M | 0.83% | 129,300 +17,300 | +15% | +$3.1M |
|